The government has intensified regulatory surveillance across the pharmaceutical supply chain following concerns over the unauthorised sale and promotion of GLP-1 based weight loss drugs in the Indian market.
The move comes amid reports of multiple generic variants becoming widely available through retail pharmacies, online platforms, wholesalers, and wellness clinics. Authorities flagged concerns that such accessibility, especially without proper medical oversight, could expose users to serious health risks and adverse effects.
According to the Health Ministry, the Drugs Controller of India has stepped up monitoring mechanisms to ensure compliance with ethical pharmaceutical practices in the distribution and use of these drugs. The regulator, in coordination with state authorities, has launched targeted enforcement actions aimed at curbing unauthorised sales and preventing misuse across different points in the supply chain.
Officials stated that regulatory checks will continue to intensify in the coming weeks, with strict action planned against violations. These include cancellation of licenses, imposition of penalties, and prosecution under applicable legal provisions.
As part of the crackdown, authorities conducted audits and inspections at 49 entities, including online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics. The inspections, carried out across multiple regions, focused on identifying irregularities such as sale without prescription, improper dispensing practices, and misleading promotional activities. Notices have been issued to entities found in violation.
Earlier, on March 10, 2026, the regulator issued a comprehensive advisory to all manufacturers, explicitly prohibiting surrogate advertising and any indirect promotion that could mislead consumers or encourage off-label usage of GLP-1 drugs. The advisory formed part of a broader effort to regulate marketing practices and prevent misuse.
The government reiterated that patient safety remains the primary concern in regulating these drugs. Officials warned that the use of GLP-1 based weight loss medications without clinical supervision could lead to severe complications, reinforcing the need for controlled access.
These drugs have been approved in India with strict conditions regarding prescription. They are authorised to be prescribed only by endocrinologists and internal medicine specialists, and in certain cases by cardiologists, depending on specific medical indications.
Authorities have advised citizens to use such medications strictly under the guidance of qualified medical practitioners and avoid procuring them through unauthorised channels.
The intensified surveillance and enforcement actions indicate a tightening regulatory approach as authorities seek to address emerging risks associated with the growing availability of weight loss drugs in the market.
